Strategic-Pharma to focus on core competency of developing worldwide regulatory strategies for emerging biotechnology companies.

Strategic-Pharma announced today that the company is narrowing its drug development services to focus solely on its key competency, namely, developing worldwide regulatory strategies. The knowledge-based company will now have a single objective - to obtain marketing approval for new therapies as quickly as possible.

Flemington, NJ (PRWEB) May 17, 2003 - Strategic-Pharma announced today that the company is narrowing its drug development services to focus solely on its key competency, namely, developing worldwide regulatory strategies. The knowledge-based company will now have a single objective - to obtain marketing approval for new therapies as quickly as possible. By concentrating solely on regulatory aspects of worldwide development, Strategic-Pharma believes it will blossom as a niche scientific company in a highly specialized market.

Development of a drug or biologic is complex and multifaceted, requiring highly specialized input from several scientific disciplines and business groups. Consequently, divisional barriers naturally separate the development process and create functional boundaries. Strategic-Pharmas consultants understand these traditional boundaries and are experienced at incorporating all the key elements into one global strategy. Due to the labyrinthine nature of drug development, the process is often overwhelming," says Dr. Richard Williams, Managing Consultant and Founder of Strategic-Pharma. For emerging biotechnology companies it is not economical to bring in highly specialized and experienced full-time personnel to develop regulatory strategy."

Regulatory strategy has an enormous impact on the highly regulated biopharmaceutical industry. An appropriate strategy can accelerate the progress for an early stage product requiring proof-of-concept" as well as expedite the development of later stage products requiring worldwide marketing approval. Conversely, a poor regulatory strategy can delay development or even prevent marketing approval of a promising therapy. Dr. Williams continues, Drug development costs hundreds of millions of dollars. Shortening development time can have an enormous impact on the return of investment as well as accelerating the availability of new drugs for patients."

Strategic-Pharma is a privately held consulting firm providing worldwide regulatory strategies for emerging biopharmaceutical companies. The strategic intent is to rapidly advance new therapies toward worldwide registration (www.strategic-pharma.com).